比利时慢性自发性荨麻疹患者奥马珠单抗治疗模式的真实世界回顾性分析
该研究为比利时一项观察性回顾性病历审查,纳入2014年8月至2016年12月启动奥马珠单抗治疗的235例成人慢性自发性荨麻疹(CSU)患者。基线平均7日荨麻疹活动度评分(UAS7)为32.0,治疗1个月后降至12.6,67.2%的患者达到UAS7≤6。研究提示部分用药未完全遵循指南,需提高指南推荐药物的处方依从性。
要点
- 奥马珠单抗治疗1个月后UAS7从基线32.0降至12.6,67.2%患者达到良好控制。
- 67.8%患者至少发生一次给药间隔延长和/或缩短,平均给药间隔4.8周。
- 87例停药患者中49.4%因症状缓解停药,12.6%因无效停药。
核心结论
- 比利时启动奥马珠单抗治疗的CSU患者基线病情严重,治疗1个月后症状显著改善。
- CSU治疗中指南推荐药物的处方依从性有待提高。
研究设计与样本
- 观察性、回顾性病历审查,纳入2014年8月至2016年12月启动奥马珠单抗治疗的成人CSU患者,最长随访28个月。
- 共纳入235例患者,从症状出现到诊断的中位时间5.4个月,从诊断到启动奥马珠单抗的中位时间6.7个月。
主要发现
- 基线平均7日荨麻疹活动度评分(UAS7)为32.0(SD 6.05),奥马珠单抗治疗1个月后改善至12.6(SD 11.2)。
- 研究期间67.2%的患者达到UAS7≤6(良好控制)。
- 奥马珠单抗平均给药间隔为4.8周(SD 1.7),67.8%的患者至少发生一次给药间隔延长和/或缩短。
- 87例患者停止奥马珠单抗且观察期结束前未再启动,最常见原因为症状缓解(49.4%),其次为缺乏疗效(12.6%)、失访(6.9%)和不良事件(3.4%)。
- 最常见不良事件为头痛(8/82),未报告过敏性休克。
关键数值与推荐
- 启动奥马珠单抗前/后使用的治疗并不总是遵循指南:26.4%/11.1%的患者接受第一代H1抗组胺药,20.4%在启动奥马珠单抗后使用单药治疗。
临床怎么用
- 真实世界中奥马珠单抗可快速改善重度CSU患者的症状,治疗1个月即可评估疗效。
- 应提高CSU治疗中对指南推荐药物处方的依从性。
局限性
- 本研究为回顾性病历审查,可能存在记录偏倚。
- 单国真实世界数据,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic spontaneous urticaria (CSU) is characterized by the repeated occurrence of persistent hives and/or angioedema for ≥6 weeks, without specific external stimuli. H1 -antihistamines have long been the standard of care of CSU, but many patients remain uncontrolled even at 4× the approved dose. Add-on therapy with omalizumab has proven effective in clinical trials, but little is known about omalizumab treatment in Belgium. OBJECTIVE: To collect real-world clinical data on omalizumab treatment in adults with CSU in Belgium. METHODS: This was an observational, retrospective chart review of adults with CSU, who initiated omalizumab treatment between August 2014 and December 2016 (maximum 28 months follow-up). RESULTS: In total, 235 patients were included (median time from symptom onset to diagnosis, 5.4 months; median time from diagnosis to commencing omalizumab, 6.7 months). Treatments used before/after commencing omalizumab did not always adhere to guidelines; many patients (26.4%/11.1%) received first-generation H1 -antihistamines, while 20.4% used omalizumab monotherapy after initiating treatment. The mean interval between omalizumab administrations was 4.8 (SD 1.7) weeks; 67.8% of patients had ≥1 interval prolongation and/or shortening. Mean baseline 7-day Urticaria Activity Score (UAS7) was 32.0 (SD 6.05); this improved to 12.6 (SD 11.2) after 1 month of omalizumab. About 67.2% of patients reached UAS7 ≤ 6 (well controlled) during the study. A total of 87 patients stopped omalizumab and never restarted before the end of the observation period; the most prevalent reason was remission of symptoms (49.4% of patients), followed by lack of effect (12.6%), lost to follow-up (6.9%) and adverse events (3.4%). Headache was the most common adverse event (n = 8/82). No anaphylaxis was reported. CONCLUSIONS: This study revealed that patients initiated on omalizumab in Belgium had severe CSU at baseline, and showed substantial improvements after 1 month of treatment. Greater adherence to the prescription of guideline-recommended medications is needed for the treatment of CSU.
引用
- Lapeere H, Baeck M, Stockman A, et al. A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real-world study in Belgium. J Eur Acad Dermatol Venereol. 2019. PMID: 31099916. doi:10.1111/jdv.15684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。